PharmChem (PharmChem) Interest Expense : $0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2003. Start your Free Trial

What is PharmChem Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. PharmChem's interest expense for the three months ended in Sep. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. PharmChem's Operating Income for the three months ended in Sep. 2023 was $ 0.30 Mil. PharmChem's Interest Expense for the three months ended in Sep. 2023 was $ 0.00 Mil. PharmChem has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

PharmChem Interest Expense Historical Data

The historical data trend for PharmChem's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmChem Interest Expense Chart

PharmChem Annual Data

Trend

Dec93

Dec94

Dec95

Dec96

Dec97

Dec98

Dec99

Dec00

Dec01

Dec02

Interest Expense

Get a 7-Day Free Trial

PharmChem Quarterly Data
	Jun99	Sep99	Dec99	Mar00	Jun00	Sep00	Dec00	Mar01	Jun01	Sep01	Dec01	Mar02	Jun02	Sep02	Dec02	Mar03	Jun03	Sep03	Sep22	Sep23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

PharmChem Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

PharmChem (OTCPK:PCHM) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

PharmChem's Interest Expense for the three months ended in Sep. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2023 was $0.30 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was $0.00 Mil.

PharmChem's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

PharmChem had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

PharmChem Inc has no debt.

PharmChem (PharmChem) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PharmChem Inc (OTCPK:PCHM) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2411 E. Loop 820 N, Fort Worth, TX, USA, 76118

Website

https://www.pharmchek.com

PharmChem Inc is engaged in selling and distributing of the PharmChek Sweat Patch Device. PharmChek is a system that uses sweat to detect the presence of illegal drugs. It consists of a transparent polyurethane outer covering, a small absorbent pad, and a release liner. Geographically the activities are carried out throughout the United States.

Executives

Alto Investors Palo	10 percent owner	470 UNIVERSITY AVENUE, PALO ALTO CA 94301
Micro Cap Partners Lp	10 percent owner

PharmChem (PharmChem) Headlines

From GuruFocus

PharmChem (PCHM) Announces Response To Opposition

By PRNewswire PRNewswire • 08-11-2021